Get the Stockscreener App
3.50
2.94%
0.10
After Hours:
3.47
-0.03
-0.86%
Cumberland Pharmaceuticals Inc stock is traded at $3.50, with a volume of 78,285.
It is up +2.94% in the last 24 hours and down -33.21% over the past month.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
See More
Previous Close:
$3.40
Open:
$3.58
24h Volume:
78,285
Relative Volume:
1.23
Market Cap:
$52.36M
Revenue:
$37.79M
Net Income/Loss:
$-10.38M
P/E Ratio:
-4.7945
EPS:
-0.73
Net Cash Flow:
$-1.00M
1W Performance:
+14.01%
1M Performance:
-33.21%
6M Performance:
+27.74%
1Y Performance:
+139.73%
1-Day Range:
$3.39
$3.61
1-Week Range:
$2.996
$3.79
52-Week Range:
$1.04
$7.25
Cumberland Pharmaceuticals Inc Stock (CPIX) Company Profile
Name
Cumberland Pharmaceuticals Inc
Sector
Phone
615-255-0068
Address
2525 WEST END AVENUE, NASHVILLE,, TN
Compare CPIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPIX
Cumberland Pharmaceuticals Inc
|
3.50 | 45.93M | 37.79M | -10.38M | -1.00M | -0.73 |
|
ZTS
Zoetis Inc
|
152.86 | 70.25B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.75 | 47.44B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.73 | 45.15B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.04 | 19.07B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
293.24 | 13.28B | 2.99B | 1.21B | 1.13B | 25.06 |
Cumberland Pharmaceuticals Inc Stock (CPIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-12 | Reiterated | UBS | Neutral |
| Feb-01-11 | Reiterated | UBS | Neutral |
| Dec-16-10 | Downgrade | UBS | Buy → Neutral |
| Aug-17-10 | Downgrade | Jefferies | Buy → Hold |
| Aug-17-10 | Reiterated | Morgan Joseph | Buy |
| Aug-17-10 | Reiterated | UBS | Buy |
| May-14-10 | Reiterated | Morgan Joseph | Buy |
View All
Cumberland Pharmaceuticals Inc Stock (CPIX) Latest News
Why Cumberland Pharmaceuticals Inc. stock attracts strong analyst attentionROI Driven Alerts - Newser
How Cumberland Pharmaceuticals Inc. stock performs during market volatilityBest Stocks for Capital Safety - Newser
What makes Cumberland Pharmaceuticals Inc. stock price move sharplyChart Breakout Alert - Newser
Caroline Young of Cumberland Pharmaceuticals buys CPIX shares By Investing.com - Investing.com Nigeria
Caroline Young of Cumberland Pharmaceuticals buys CPIX shares - Investing.com Australia
Cumberland Pharma CEO A J Kazimi buys shares worth $807 - Investing.com Australia
Cumberland Pharma CEO A J Kazimi buys shares worth $807 By Investing.com - Investing.com South Africa
Cumberland Pharmaceuticals Advances Ifetroban Study for SSc and SSc-PAH - TipRanks
Cumberland Pharmaceuticals Inc.(NasdaqGS:CPIX) added to Russell Microcap Growth Index - MarketScreener
Breakthrough DMD Heart Disease Treatment: New Drug Shows 5.4% Cardiac Function Improvement in Phase 2 Trial - Stock Titan
Asthma Market to Expand Significantly by 2034, States - openPR.com
Asthma Market to Expand Significantly by 2034, States DelveInsight Report | GSK, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentech - Barchart.com
Two Sigma Investments LP Has $89,000 Stake in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) - Defense World
Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Cross Above Two Hundred Day Moving Average – Here’s Why - Defense World
Cumberland pharmaceuticals director Kenneth Krogulski acquires $4,824 in stock By Investing.com - Investing.com South Africa
Cumberland pharmaceuticals director Kenneth Krogulski acquires $4,824 in stock - Investing.com
Dilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies | DelveInsight - GlobeNewswire Inc.
Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above 200 Day Moving Average – Time to Sell? - Defense World
Investors in Cumberland Pharmaceuticals (NASDAQ:CPIX) have seen splendid returns of 235% over the past year - Yahoo
NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS - PR Newswire
Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World
Q&A: Cumberland Pharmaceuticals CEO A.J. Kazimi weighs in on industry challenges, strengths - The Business Journals
Cumberland CEO A.J. Kazimi: Pharmaceutical tariffs would be 'concerning' - The Business Journals
Dimensional Fund Advisors LP Cuts Stock Position in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) - Defense World
Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025 - The Victoria Advocate
Cumberland, Qureight Collaborate on Lung Disease Treatment Trial - marketscreener.com
CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH - PR Newswire
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q1 2025 Earnings Call Transcript - Insider Monkey
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Held Back By Insufficient Growth Even After Shares Climb 30% - simplywall.st
Cumberland Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks
Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Rating Upgraded by StockNews.com - Defense World
Cumberland Pharmaceuticals Reports Strong Q1 2025 Growth - TipRanks
Cumberland Pharmaceuticals Inc (CPIX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Cumberland: Q1 Earnings Snapshot - MySA
Cumberland Pharmaceuticals Inc Reports Q1 2025 Earnings: EPS at $0.16, Revenue Hits $11.7 Million - GuruFocus
Earnings call transcript: Cumberland Pharmaceuticals sees Q1 2025 revenue jump 38% - Investing.com
Cumberland Pharmaceuticals Inc.Common Stock (NQ: CPIX - FinancialContent
Renaissance Technologies LLC Sells 21,000 Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) - Defense World
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE - marketscreener.com
Cumberland Pharmaceuticals Shareholders Approve Key Proposals By Investing.com - Investing.com India
Cumberland Pharmaceuticals Shareholders Approve Key Proposals - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Cumberland Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Cumberland Pharmaceuticals Inc Stock (CPIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):